Shenghao Tu
- Pharmacology top 2%
- Pharmacological Effects of Natural Compounds 9
-
- Natural Compounds in Disease Treatment 7
- Rheumatology top 5%
- Rheumatoid Arthritis Research and Therapies 21
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies 9
- Geriatrics and Gerontology top 5%
-
- Autoimmune and Inflammatory Disorders Research 10
-
- Gout, Hyperuricemia, Uric Acid 8
-
- Cytokine Signaling Pathways and Interactions 7
-
- Inflammasome and immune disorders 6
- Journals
- The Lancet (1 paper)SHILAP Revista de lepidopterología (1 paper)Frontiers in Immunology (7 papers)
- Partner nations
- ChinaAustraliaUnited States
In The Last Decade
Shenghao Tu
68 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 127
- Pharmacology 219
- Complementary and alternative medicine 177
- Rheumatology 308
- Infectious Diseases 327
- Geriatrics and Gerontology 56
Countries citing papers authored by Shenghao Tu
This map shows the geographic impact of Shenghao Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shenghao Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shenghao Tu more than expected).
Fields of papers citing papers by Shenghao Tu
This network shows the impact of papers produced by Shenghao Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shenghao Tu. The network helps show where Shenghao Tu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shenghao Tu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 4 | |
| 4 | 2023 | 15 | |
| 5 | 2023 | 11 | |
| 6 | 2022 | 4 | |
| 7 | 2022 | 37 | |
| 8 | 2021 | 9 | |
| 9 | 2021 | 65 | |
| 10 | 2020 | 6 | |
| 11 | 2020 | 24 | |
| 12 | 2020 | 21 | |
| 13 | 2020 | 7 | |
| 14 | 2019 | 15 | |
| 15 | 2019 | 12 | |
| 16 | 2019 | 40 | |
| 17 | 2017 | 20 | |
| 18 | 2016 | 29 | |
| 19 | 2013 | 41 | |
| 20 | 1995 | 2 |
About Shenghao Tu
Shenghao Tu is a scholar working on Rheumatology, Nephrology and Complementary and alternative medicine, having authored 70 papers that have together received 1.7k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (21 papers), Autoimmune and Inflammatory Disorders Research (10 papers), COVID-19 Clinical Research Studies (9 papers), Pharmacological Effects of Natural Compounds (9 papers), Gout, Hyperuricemia, Uric Acid (8 papers), Natural Compounds in Disease Treatment (7 papers), Cytokine Signaling Pathways and Interactions (7 papers) and Inflammasome and immune disorders (6 papers). The work is most often cited by research in Pharmacology (219 citations), Complementary and alternative medicine (177 citations) and Rheumatology (308 citations). Shenghao Tu has collaborated with scholars based in China, Australia and United States. Frequent co-authors include Ying Huang, Pan Shen, Kai Qin, Weiji Lin, Xin Ba, Zhe Chen, Yao Huang, Liang Han, Zhe Chen and Yu Wang. Their work appears in journals such as The Lancet, SHILAP Revista de lepidopterología and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.